PRINCETON, NJ – Apr. 5. 2017 – Certara today announced that its d3 Medicine company has been selected to conduct a national audit of Australia’s medical countermeasures (MCM) product research and development (R&D) capabilities and capacity.
https://www.certara.com/pressrelease/certaras-d3-medicine-partners-with-the-australian-department-of-defence/Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities PRINCETON, N.J.— September 22, 2021. Certara, a global leader in biosimulation, today announced that it is expanding its Integrated Drug Development (IDD) division with a new clinical science group, headed up by Philippa Marshall, M.D., Vice President of Clinical Science. The Company also appointed David Mitchell, … Continued
https://www.certara.com/pressrelease/certara-announces-new-clinical-science-group-and-adds-senior-scientific-experts/How can the latest modeling and simulation technologies accelerate drug discovery and development? We frequently receive questions about why model-informed drug development (MIDD) is so critical to informing the development of safer and more effective new drugs? Indeed, all drug discovery and development today involves some level of MIDD, a term that encompasses a large … Continued
https://www.certara.com/blog/essentials-of-model-informed-drug-development-midd-top-down-vs-bottom-up-approaches/Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19
https://www.certara.com/pressrelease/certara-and-dmtc-ltd-announce-research-collaboration-to-study-preventative-use-of-chloroquine-in-health-care-workers-at-high-risk-for-covid-19/Certara participated in the pretomanid development program providing scientific support to the TB Alliance and the Bill & Melinda Gates Foundation.
https://www.certara.com/blog/certara-scientists-support-tb-alliances-groundbreaking-new-drug/PRINCETON, NJ – July 9, 2019 – Certara has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.
https://www.certara.com/pressrelease/certara-announces-the-formation-of-a-new-practice-area-focused-on-global-health/PRINCETON, NJ – Nov. 14, 2018 – Certara today announced that it has been awarded two new dermal virtual bioequivalence grants by the US Food and Drug Administration (FDA).
https://www.certara.com/pressrelease/us-fda-awards-certaras-simcyp-division-two-new-dermal-virtual-bioequivalence-grants/In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.
https://www.certara.com/on-demand-webinar/using-virtual-twin-technology-to-predict-drug-exposure-in-individual-patients/